DK0841907T3 - Anvendelse af agonister eller antagonister for P2 purinreceptorer til forebyggelse af glutamatfremkaldt cytotoksicitet - Google Patents

Anvendelse af agonister eller antagonister for P2 purinreceptorer til forebyggelse af glutamatfremkaldt cytotoksicitet

Info

Publication number
DK0841907T3
DK0841907T3 DK96927588T DK96927588T DK0841907T3 DK 0841907 T3 DK0841907 T3 DK 0841907T3 DK 96927588 T DK96927588 T DK 96927588T DK 96927588 T DK96927588 T DK 96927588T DK 0841907 T3 DK0841907 T3 DK 0841907T3
Authority
DK
Denmark
Prior art keywords
agonists
antagonists
glutamate
induced cytotoxicity
purine receptors
Prior art date
Application number
DK96927588T
Other languages
English (en)
Inventor
Cinzia Volonte
Daniela Merlo
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Application granted granted Critical
Publication of DK0841907T3 publication Critical patent/DK0841907T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK96927588T 1995-07-28 1996-07-24 Anvendelse af agonister eller antagonister for P2 purinreceptorer til forebyggelse af glutamatfremkaldt cytotoksicitet DK0841907T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI001649A IT1277373B1 (it) 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
PCT/EP1996/003254 WO1997004760A1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity

Publications (1)

Publication Number Publication Date
DK0841907T3 true DK0841907T3 (da) 2002-07-15

Family

ID=11372076

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96927588T DK0841907T3 (da) 1995-07-28 1996-07-24 Anvendelse af agonister eller antagonister for P2 purinreceptorer til forebyggelse af glutamatfremkaldt cytotoksicitet

Country Status (15)

Country Link
US (2) US6326370B1 (da)
EP (1) EP0841907B1 (da)
JP (1) JPH11511126A (da)
AT (1) ATE216878T1 (da)
AU (1) AU707808B2 (da)
BR (1) BR9609856A (da)
CA (1) CA2224293A1 (da)
DE (1) DE69621022T2 (da)
DK (1) DK0841907T3 (da)
ES (1) ES2173307T3 (da)
HK (1) HK1015698A1 (da)
IL (1) IL122915A (da)
IT (1) IT1277373B1 (da)
RU (1) RU2211707C2 (da)
WO (1) WO1997004760A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615202D0 (en) * 1996-07-19 1996-09-04 Smithkline Beecham Plc Pharmaceuticals
SE9702002D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
IT1303815B1 (it) * 1998-12-02 2001-02-23 Consiglio Nazionale Ricerche Impiego di selettivi composti modulatori dei recettori purinici p2 perla prevenzione dei danni e della mortalita' causata da ischemia
US7141511B2 (en) * 2004-04-27 2006-11-28 Micron Technology Inc. Method and apparatus for fabricating a memory device with a dielectric etch stop layer
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
EP3323415A1 (en) * 2016-11-16 2018-05-23 Institut du Cerveau et de la Moelle Epiniere-ICM Treatment of neurodegenerative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4230493A1 (de) 1992-09-11 1994-03-17 Institut Fuer Bioanalytik Gmbh Arzneimittel zur Behandlung des zentralen Nervensystems

Also Published As

Publication number Publication date
HK1015698A1 (en) 1999-10-22
ITMI951649A0 (it) 1995-07-27
ES2173307T3 (es) 2002-10-16
EP0841907A1 (en) 1998-05-20
AU707808B2 (en) 1999-07-22
IT1277373B1 (it) 1997-11-10
RU2211707C2 (ru) 2003-09-10
AU6736696A (en) 1997-02-26
ITMI951649A1 (it) 1997-01-27
ATE216878T1 (de) 2002-05-15
IL122915A0 (en) 1998-08-16
BR9609856A (pt) 1999-03-16
DE69621022T2 (de) 2003-02-27
CA2224293A1 (en) 1997-02-13
EP0841907B1 (en) 2002-05-02
IL122915A (en) 2003-05-29
US20020028790A1 (en) 2002-03-07
WO1997004760A1 (en) 1997-02-13
US6326370B1 (en) 2001-12-04
JPH11511126A (ja) 1999-09-28
DE69621022D1 (de) 2002-06-06

Similar Documents

Publication Publication Date Title
EP0550631A4 (en) Compounds having antihypertensive and anti-ischemic properties
MY112231A (en) Pharmaceutical and other dosage forms
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
BR9812230A (pt) Artigo abrasivo, e, processos para produzir o mesmo, para reduzir uma superfìcie de uma peça de trabalho, e para utilizar um artigo abrasivo para reduzir a superfìcie de uma peça de trabalho
DK0841907T3 (da) Anvendelse af agonister eller antagonister for P2 purinreceptorer til forebyggelse af glutamatfremkaldt cytotoksicitet
BR9814880A (pt) HormÈnios de glicoproteìna bifuncionais de cadeia única
TW217407B (da)
IL132682A0 (en) Topical compositions
DE69329598D1 (de) An beta-caroten angereicherte essfertige getreideprodukte
BRPI0410159A (pt) corrente transportadora articulada, pino de corrente para a mesma, e, uso de uma liga de aço
AU2003288053A1 (en) Partially quaternised, amino-functional organopolysiloxanes and their use in aqueous systems
DE59707340D1 (de) Verhinderung und verzögerung der belagsbildung in membranprozessen
BR9809253A (pt) Processo para o ajuste de um leito fluidizado circulante e utilização do processo
JPS6470417A (en) Method and composition for treating psoriasis
YU40398A (sh) Kompozicija nazalnog spreja za davanje sredstva za lečenje odloženog napada emezisa
DE69924757D1 (de) Zusammensetzung aus nicht-halogeniertem polyamid
NO992298L (no) Konformasjonsbegrensede LH-RH analoger, anvendelse derav og farmas°ytiske sammensetninger inneholdende disse
BR9809482A (pt) Composição detergente particulada.
ATE213242T1 (de) Neue verbindungen, welche antagonisten sind für p2-purinorezeptor 7-transmembran (tm) g-protein gekoppelte rezeptoren
EP0979650A4 (en) ANTIVIRUS MEDIUM
Wang et al. Study on dewetting and fracture behavior of HTPB propellants by SEM
NO983552L (no) Ny s°tningssammensetning med umiddelbar oppl°selighet inneholdende neohesperidindihydrokalkon og minst ett annet h°yintensitets-s°tningsmiddel
Bailey et al. Liver Toxicity in Rats Fed A Mixture of Pcb Congeners and 2, 3, 7, 8-Tcdd
Abovyan et al. Activated combustion of the SiO sub 2-Al-C mixture and synthesis of the SiC/Al sub 2 O sub 3 composite powders
KURAUCHI The Development and Application of Powder Coating